Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | HBB | P68871 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.40 |
| ▸ | ADH1B | P00325 | 1/20 | 0.39 |
| ▸ | ADH1C | P00326 | 1/20 | 0.39 |
| ▸ | ADH1A | P07327 | 1/20 | 0.39 |
| ▸ | ADH7 | P40394 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL6252873 | 0.92 | NPC1 (0.51) | KDM4EALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL5542553 | 0.85 | NPC1 (0.46) | KDM4EALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL19017833 | 0.81 | P2RX7 (0.43) | KDM4EALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL22854882 | 0.81 | HPGD (0.42) | KDM4EALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL26568731 | 0.81 | P2RX7 (0.43) | KDM4EALDH1A1P2RX7ADH1BADH1C | |
| SCHEMBL15476680 | 0.81 | KDM4E (0.53) | KDM4EALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL12614430 | 0.81 | KDM4E (0.50) | KDM4EALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL20807129 | 0.81 | KDM4E (0.50) | KDM4EALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL23997635 | 0.80 | KDM4E (0.42) | KDM4EALDH1A1ADH1BADH1CADH1A | |
| SCHEMBL24404417 | 0.79 | SMN1; SMN2 (0.40) | KDM4EALDH1A1NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1377560-B1 | PIPERAZINE DERIVATIVES AS TACHYKININ ANTAGONISTS | GLAXO GROUP LTD (GB) | 2005-09-21 | — | — | EP | claimed |
| EP-3954679-A2 | AMIDE COMPOUNDS FOR THE TREATMENT OF HIV INFECTIONS | Gilead Sciences, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3235811-A1 | PROCESS OF PREPARING OXALAMIDES | Senomyx, Inc. (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20140371198-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2014-12-18 | — | — | US | disclosed |
| US-8759334-B2 | Compounds useful for the treatment of metabolic and inflammatory diseases | GALAPAGOS NV (BE) | 2014-06-24 | — | — | US | disclosed |
| EP-2665704-A1 | AZETIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF METABOLIC AND INFLAMMATORY DISEASES | Galapagos NV (BE) | 2013-11-27 | — | — | EP | disclosed |
| US-20130303515-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2013-11-14 | — | — | US | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| WO-2012098033-A1 | AZETIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF METABOLIC AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2012-07-26 | — | — | WO | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1377560-B1 | PIPERAZINE DERIVATIVES AS TACHYKININ ANTAGONISTS | GLAXO GROUP LTD (GB) | 2005-09-21 | — | — | EP | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-20040157858-A1 | Piperazine derivatives as tachykinin antagonists | GLAXO GROUP LIMITED (GB) | 2004-08-12 | — | — | US | disclosed |
| EP-1377560-A1 | PIPERAZINE DERIVATIVES AS TACHYKININ ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2004-01-07 | — | — | EP | disclosed |
| WO-2002081461-A1 | PIPERAZINE DERIVATIVES AS TACHYKININ ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | KDM4E 4854/4885ALDH1A1 355/4885NPC1 2404/4885 |
| US-20140371198-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC AND INFLAMMATORY DISEASES | GOT2, GPR119, PC | KDM4E 3725/4885ALDH1A1 1373/4885NPC1 432/4885 |
| US-20040157858-A1 | Piperazine derivatives as tachykinin antagonists | NPSR1, SSTR2, PROKR1 | KDM4E 2642/4885ALDH1A1 2184/4885NPC1 736/4885 |
| US-20130303515-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC AND INFLAMMATORY DISEASES | GOT2, GPR119, PC | KDM4E 3725/4885ALDH1A1 1373/4885NPC1 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.